Literature DB >> 10693686

Aggressive surgery is unwarranted for biliary tract rhabdomyosarcoma.

S L Spunt1, T E Lobe, A S Pappo, D M Parham, M D Wharam, C Arndt, J R Anderson, W M Crist, C Paidas, E Wiener, R J Andrassy, C L Schwartz.   

Abstract

BACKGROUND/
PURPOSE: Rhabdomyosarcoma (RMS) of the biliary tract is rare, and, in addition to multiagent chemotherapy with or without radiotherapy (RT), some investigators recommend aggressive surgery. To assess the role of surgery, records of all 25 eligible patients with biliary RMS enrolled in IRSG studies I through IV from 1972 to 1998 were reviewed.
METHODS: Treatment included surgery with or without vincristine, dactinomycin, cyclophosphamide, doxorubicin, cisplatin, etoposide, ifosfamide, and with or without RT. Data evaluated included clinical presentation, treatment, complications, and outcome.
RESULTS: Diagnostic imaging identified the primary tumor but failed to identify regional metastases. Despite aggressive surgery, gross total resection at diagnosis was possible in only 6 cases, 2 of which had negative surgical margins. Although only 6 (29%) patients without distant metastases underwent gross total resection, estimated 5-year survival rate was 78% (95% CI 58%, 97%). Infectious complications were common and frequently associated with external biliary drains. Five (20%) died within the first 2 months, 3 of sepsis.
CONCLUSIONS: Surgery is critical for establishing an accurate diagnosis and determining the extent of regional disease. Gross total resection is rarely possible despite aggressive surgery, and outcome is good despite residual disease after surgery. External biliary drains increase the risk of postoperative infectious complications.

Entities:  

Mesh:

Year:  2000        PMID: 10693686     DOI: 10.1016/s0022-3468(00)90030-7

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  23 in total

1.  Biliary rhabdomyosarcoma.

Authors:  Norihiko Kitagawa; Noriko Aida
Journal:  Pediatr Radiol       Date:  2007-07-27

Review 2.  Differential diagnosis and management of liver tumors in infants.

Authors:  Israel Fernandez-Pineda; Rosa Cabello-Laureano
Journal:  World J Hepatol       Date:  2014-07-27

Review 3.  ERCP with intracholedocal biopsy for the diagnosis of biliary tract rhabdomyosarcoma in children.

Authors:  F Scottoni; P De Angelis; L Dall'Oglio; P Francalanci; L Monti; J de Ville de Goyet
Journal:  Pediatr Surg Int       Date:  2013-02-17       Impact factor: 1.827

4.  [Rhabdomyosarcoma of the common bile duct mimicking choledochal cyst: a rare cause of obstructive jaundice].

Authors:  Hassan Nazmul; Islam Rafiqul; Fathema Kaniz; Sayeed Maimuna; Wahiduzzaman Mazumder Md; Bazlul Karim Asm; Pada Dey Bishnu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2020-12

Review 5.  Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.

Authors:  Venkatesh P Kashi; Mark E Hatley; Rene L Galindo
Journal:  Nat Rev Cancer       Date:  2015-07       Impact factor: 60.716

Review 6.  Imaging of biliary disorders in children.

Authors:  Céline Rozel; Laurent Garel; Françoise Rypens; Loïc Viremouneix; Chantale Lapierre; Jean Claude Décarie; Josée Dubois
Journal:  Pediatr Radiol       Date:  2010-09-24

Review 7.  Pediatric Biliary Interventions in the Native Liver.

Authors:  Lisa H Kang; Colin N Brown
Journal:  Semin Intervent Radiol       Date:  2016-12       Impact factor: 1.513

8.  Rhabdomyosarcoma of biliary tract- a diagnostic dilemma.

Authors:  V Kumar; S Chaudhary; M Kumar; A N Gangopadhyay
Journal:  Indian J Surg Oncol       Date:  2012-10-06

9.  A mouse model of rhabdomyosarcoma originating from the adipocyte lineage.

Authors:  Mark E Hatley; Wei Tang; Matthew R Garcia; David Finkelstein; Douglas P Millay; Ning Liu; Jonathan Graff; Rene L Galindo; Eric N Olson
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

10.  Botryoid rhabdomyosarcoma of common bile duct.

Authors:  Kiran Aggarwal; Sangeeta Pahuja; Rajeev Chadha
Journal:  Indian J Pediatr       Date:  2004-04       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.